{"Clinical Trial ID": "NCT00654836", "Intervention": ["INTERVENTION 1:", "Carboplatin, ABI-007 and Bevacizumab", "For patients with haematological toxicity, bevacizumab was administered at 10mg/kg on days 1 and 15. Similarly, for patients with no haematological toxicity, a standard dose of carboplatin according to the participant's area under the plasma concentration curve (AUC-6) was administered on days 1, 22 and 43. For patients with haematological toxicity, carboplatin was administered only on day 1. Finally, for patients with no haematological toxicity, ABI-007 (Abraxane) 100mg/m2 was administered on days 1, 15, 22, 29, 36,43 and 50. Conversely, for patients with haematological toxicity, Abraxane was administered only at 100mg/m2 only on days 1 and 15."], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "A primary adenocarcinoma confirmed histologically or cytologically in the breast", "A local recidivant or metastatic disease", "Must have negative HER-2 breast cancer or, if HER-2 positive, must be unable to receive trastuzumab (Herceptin\u00ae) or have previously received trastuzumab", "A measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (the longest diameter to be recorded) as > 20 mm by conventional techniques or > 10 mm by spiral scan.", "No known CNS disease", "Unspecified hormonal receptor status", "CHARACTERISTICS OF PATIENTS:", "\u2022 Inclusion criteria:", "Postmenopausal status not specified", "\u2022 ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%", "Life expectancy > 12 weeks", "WBC 3000/mcL", "Absolute neutrophil count 1,500/mcL", "Number of platelets 100 000/mcL", "Total normal bilirubin", "ASAT and ALT 2.5 times the upper limit of normal (ULN)", "ALKALINE phosphatase 2.5 times ULN (unless bone metastases are present in the absence of liver metastases)", "Creatinine 1.5 mg/dL", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective contraception", "No other concomitant malignancies over the past 5 years, except for skin cancer of basal or epidermal cells or in situ cervical carcinoma", "- Exclusion criteria:", "\u2022 Pre-existing neuropathy grade 1", "An uncontrolled intercurrent disease, including, but not limited to, one of the following:", "Permanent or active infection", "- Symptomatic congestive heart failure", "\u266a Unstable angina pectoris \u266a", "Cardiac arrhythmia", "A serious, non-healing injury, ulcer or bone fracture", "A psychiatric illness or social situations that would limit compliance with the requirements of the study", "Inadequately controlled hypertension (defined as systolic blood pressure > 150 mm Hg and/or diastolic blood pressure > 100 mm Hg on antihypertensive medicinal products)", "History of hypertensive seizure or hypertensive encephalopathy", "New York Heart Association Class II-IV Congestive Heart Failure", "History of myocardial infarction or unstable angina in the last 6 months", "History of stroke or transient ischemic attack in the last 6 months", "A major vascular disease (e.g. aortic aneurysm, aortic dissection)", "A symptomatic peripheral vascular disease", "Evidence of haemorrhagic diathesis or coagulopathy", "A major traumatizing injury in the last 28 days", "History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscesses in the last 6 months", "- Proteinuria, as either urine-proteinuria ratio has shown: creatinine 1.0 OR urinary prick for proteinuria 2+", "Patients who have discovered 2+ proteinuria during dipstick urine analysis at the beginning of the study should have a 24-hour urinary protein 1g", "History of allergy or hypersensitivity to the formulation of nanoparticles stabilized by paclitaxel albumin, paclitaxel, bevacizumab, carboplatin, albumin, excipients of pharmaceutical products or similar chemical agents", "THERAPE PRIOR CONCURENT:", "See Disease Characteristics", "- Recovered from any previous treatment", "No previous chemotherapy for a local recurrent or metastatic disease", "\u2022 Previous neoadjuvant or adjuvant chemotherapy is allowed", "More than a week since prior nucleus biopsy or other minor surgery, excluding the installation of a vascular access device", "More than 4 weeks since major surgery and no concomitant major surgery or open biopsy", "More than 4 weeks since prior radiation therapy", "More than 4 weeks since previous chemotherapy (6 weeks for nitrosourea or mitomycin C)", "At least 1 year since the previous taxane regime", "No other competing search agent", "Concomitant anticoagulation is permitted, provided that the following criteria are met:", "- Stable dose of warfarin or heparin of low molecular weight", "INR in the desired range (2-3)", "No signs of active bleeding or coagulopathy", "No combination antiretroviral therapy concomitantly for HIV-positive patients", "No other simultaneous radiotherapy, chemotherapy, immunotherapy or hormonal antitumour treatment"], "Results": ["Performance measures:", "- Survivors without progression", "The progression is defined using the criteria for assessing response in solid tumour criteria (RECIST v1.0), such as a 20% increase in the sum of the longest diameter of the target lesions, or a measurable increase in non-target injury, or the occurrence of new lesions.", "Time limit: 30 months", "Results 1:", "Title of the arm/group: Carboplatin, ABI-007 and Bevacizumab", "For patients with haematological toxicity, bevacizumab was administered at 10mg/kg on days 1 and 15. Similarly, for patients without haematological toxicity, a standard dose of carboplatin was administered at days 1, 22 and 43 for patients with haematological toxicity, and for patients without haematological toxicity, ABI-007 (Abraxane) 100mg/m2 was administered on days 1, 8, 22, 29, 36, 43 and 50. Inversely, for patients with haematological toxicity only, ABI-007 (Abraxane) 100mg/m2 was administered on days 1, 22, 36, 43 and 50. Inversely, for patients with haematological toxicity only, ABI-007 (Abraxane) 100mg/m2 was administered on days 1, 22, 36, 43 and 50.", "Total number of participants analysed: 32", "Median (95% confidence interval)", "Unit of measure: Month 16 (9.80-22.20)"], "Adverse Events": ["Undesirable Events 1:", "Total: 24/32 (75.0%)", "* [1]24/32 (75.0%)"]}